Nephro-Urology Monthly

Published by: Kowsar

Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient

Simin Dashti-Khavidaki 1 , * , Lida Shojaie 2 , Amin Hosni 2 , Mohammad Reza Khatami 1 and Atefeh Jafari 2
Authors Information
1 Nephrology Research Center, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Article information
  • Nephro-Urology Monthly: May 01, 2015, 7 (3); e27073
  • Published Online: May 23, 2015
  • Article Type: Research Article
  • Received: January 17, 2015
  • Accepted: February 9, 2015
  • DOI: 10.5812/numonthly.7(3)2015.27073

To Cite: Dashti-Khavidaki S, Shojaie L, Hosni A, Khatami M R, Jafari A. Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient, Nephro-Urol Mon. 2015 ; 7(3):e27073. doi: 10.5812/numonthly.7(3)2015.27073.

Copyright © 2015, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Levine MH, Abt PL. Treatment options and strategies for antibody mediated rejection after renal transplantation. Semin Immunol. 2012; 24(2): 136-42[DOI][PubMed]
  • 2. Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen JP, Suberbielle C, Anglicheau D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet. 2013; 381(9863): 313-9[DOI][PubMed]
  • 3. Barba J, Zudaire JJ, Robles JE, Rosell D, Berian JM, Pascual I. Complications of kidney transplantation with grafts from expanded criteria donors. World J Urol. 2013; 31(4): 893-900[DOI][PubMed]
  • 4. Amer H, Sibulesky L, Wadei HM. Complications of Kidney Transplantation. 2013; [DOI]
  • 5. White NB, Greenstein SM, Cantafio AW, Schechner R, Glicklich D, McDonough P, et al. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation. 2004; 78(5): 772-4[PubMed]
  • 6. Djamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant. 2014; 14(2): 255-71[DOI][PubMed]
  • 7. Schinstock C, Stegall MD. Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management. Curr Transplant Rep. 2014; 1(2): 78-85
  • 8. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol. 2007; 18(4): 1046-56[DOI][PubMed]
  • 9. John R, Herzenberg AM. Our approach to a renal transplant biopsy. J Clin Pathol. 2010; 63(1): 26-37[DOI][PubMed]
  • 10. Gloor JM, Winters JL, Cornell LD, Fix LA, DeGoey SR, Knauer RM, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant. 2010; 10(3): 582-9[PubMed]
  • 11. Kim M, Martin ST, Townsend KR, Gabardi S. Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy. 2014; 34(7): 733-44[DOI][PubMed]
  • 12. Montgomery RA, Cozzi E, West LJ, Warren DS. Humoral immunity and antibody-mediated rejection in solid organ transplantation. Semin Immunol. 2011; 23(4): 224-34[DOI][PubMed]
  • 13. Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012; 94(8): 775-83[DOI][PubMed]
  • 14. Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013; 11(3): 481-90[DOI][PubMed]
  • 15. Ireland R. Thrombotic microangiopathy: rituximab in severe autoimmune TTP. Nat Rev Nephrol. 2012; 8(3): 131[DOI][PubMed]
  • 16. Clark WF. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange. Semin Dial. 2012; 25(2): 214-9[PubMed]
  • 17. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014; 371(7): 654-66[DOI][PubMed]
  • 18. Froissart A, Buffet M, Veyradier A, Poullin P, Provot F, Malot S, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012; 40(1): 104-11[DOI][PubMed]
  • 19. Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010; 115(8): 1500-11[DOI][PubMed]
  • 20. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant. 2010; 10(7): 1517-23[PubMed]
  • 21. Jodele S, Laskin BL, Goebel J, Khoury JC, Pinkard SL, Carey PM, et al. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? Transfusion. 2013; 53(3): 661-7[PubMed]
  • 22. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001; 345(10): 747-55[DOI][PubMed]
  • 23. Frank MM, Miletic VD, Jiang H. Immunoglobulin in the Control of Complement Action. Immunol Res. 2000; 22(2-3): 137-46
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments